Galderma Group AG (XSWX:GALD) Loans Receivable: CHF0 Mil (As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF172.85
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Loans Receivable?

Galderma Group AG XSWX:GALD -0.89% 15 Loans Receivable is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Galderma Group AG's Loans Receivable for the quarter that ended in Dec. 2025 was CHF0 Mil.

Galderma Group AG Loans Receivable Related Terms

Galderma Group AG Loans Receivable Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Loans Receivable Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
0.00 0.00 0.00 0.00 0.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of CHF0 Mil mean?
Galderma Group AG (XSWX:GALD) has a Loans Receivable of CHF0 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Loans Receivable too high?
Galderma Group AG's current Loans Receivable is CHF0 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Loans Receivable compare to ZTS and UTHR?
Galderma Group AG's Loans Receivable of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Loans Receivable is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Loans Receivable of CHF0 Mil. The current Loans Receivable is CHF0 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Loans Receivable is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF172.85
Price